United States set
Menu Shopping cart $0 Search
Manufactured by BioVendor

Human Osteopontin ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA
  • Other names:OPN
  • Species:Human
Cat. No. Size Price

New RBL009R 96 wells (1 kit) $526,55
PubMed Product Details
Technical Data


Sandwich ELISA


Serum, Plasma

Sample Requirements

6 µl/well


Shipped on blue ice packs. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Range

125 - 4 000 pg/ml

Limit of Detection

31 pg/ml

Intra-assay (Within-Run)

n = 8
CV = 3.5%

Inter-assay (Run-to-Run)

n = 8
CV = 4.1%

Spiking Recovery


Dilution Linearity




It is intended for research use only

The total assay time is less than 5 hours

The kit measures total osteopontin

Assay format is 96 wells

Standard is a recombinant protein

Components of the kit are provided ready to use, concentrated or dried

Research topic

Bone and cartilage metabolism, Cardiovascular disease, Diabetology - Other Relevant Products, Energy metabolism and body weight regulation, Immune Response, Infection and Inflammation, Neural tissue markers, Oncology, Renal disease


Osteopontin (OPN), a secreted multifunctional phosphoprotein, is a member of the small integrin-binding ligand N-linked glycoprotein (SIBLING) family of cell matrix proteins and participates in many biological activities. OPN has been demonstrated to be closely related to the occurrence and development of many bone-related diseases, such as osteoporosis, rheumatoid arthritis, and osteosarcoma. Besides that, it functions as a proinflammatory cytokine and promotes cell-mediated immune responses, and also has protective functions such as biomineralization and wound healing, and is also a strong predictor of adverse outcomes in patients with CVDs. Thus, OPN is not only a risk factor but also a potential therapeutic target for CVDs.

Summary References (19)

References to Osteopontin

  • Ahmad R, Al-Mass A, Al-Ghawas D, Shareif N, Zghoul N, Melhem M, Hasan A, Al-Ghimlas F, Dermime S, Behbehani K. Interaction of osteopontin with IL-18 in obese individuals: implications for insulin resistance. PLoS One. 2013;8 (5):e63944
  • Bertola A, Deveaux V, Bonnafous S, Rousseau D, Anty R, Wakkach A, Dahman M, Tordjman J, Clement K, McQuaid SE, Frayn KN, Huet PM, Gugenheim J, Lotersztajn S, Le Marchand-Brustel Y, Tran A, Gual P. Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes. 2009 Jan;58 (1):125-33
  • Braitch M, Nunan R, Niepel G, Edwards LJ, Constantinescu CS. Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. Arch Neurol. 2008 May;65 (5):633-5
  • Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA, Chambers AF. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res. 2006 Jun 1;12 (11 Pt 1):3337-43
  • Cho EH, Cho KH, Lee HA, Kim SW. High serum osteopontin levels are associated with low bone mineral density in postmenopausal women. J Korean Med Sci. 2013 Oct;28 (10):1496-9
  • Comi C, Carecchio M, Chiocchetti A, Nicola S, Galimberti D, Fenoglio C, Cappellano G, Monaco F, Scarpini E, Dianzani U. Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer's disease and its levels correlate with cognitive decline. J Alzheimers Dis. 2010;19 (4):1143-8
  • El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 2006 Dec;17 (6):463-74
  • Gao SG, Li KH, Zeng KB, Tu M, Xu M, Lei GH. Elevated osteopontin level of synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis patients. Osteoarthritis Cartilage. 2010 Jan;18 (1):82-7
  • Haider HM, Amin IR, Ahmad KA. Plasma and synovial osteopontin levels, are they associated with disease severity of primary knee osteoarthritis in Egyptian patients?. Egypt Rheumatologist . 2015;37:29-34
  • Inoue M, Shinohara ML. Intracellular osteopontin (iOPN) and immunity. Immunol Res. 2011 Apr;49 (1-3):160-72
  • Iwadate H, Kobayashi H, Kanno T, Asano T, Saito R, Sato S, Suzuki E, Watanabe H, Ohira H. Plasma osteopontin is correlated with bone resorption markers in rheumatoid arthritis patients. Int J Rheum Dis. 2014 Jan;17 (1):50-6
  • Kahles F, Findeisen HM, Bruemmer D. Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes. Mol Metab. 2014 Jul;3 (4):384-93
  • Kariya Y, Kariya Y, Saito T, Nishiyama S, Honda T, Tanaka K, Yoshida M, Fujihara K, Hashimoto Y. Increased cerebrospinal fluid osteopontin levels and its involvement in macrophage infiltration in neuromyelitis optica. BBA Clin. 2015 Jun;3:126-34
  • Kiefer FW, Zeyda M, Gollinger K, Pfau B, Neuhofer A, Weichhart T, Saemann MD, Geyeregger R, Schlederer M, Kenner L, Stulnig TM. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes. 2010 Apr;59 (4):935-46
  • Kiefer FW, Zeyda M, Todoric J, Huber J, Geyeregger R, Weichhart T, Aszmann O, Ludvik B, Silberhumer GR, Prager G, Stulnig TM. Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology. 2008 Mar;149 (3):1350-7
  • Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. J Cell Commun Signal. 2009 Dec;3 (3-4):311-22
  • Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin--a molecule for all seasons. QJM. 2002 Jan;95 (1):3-13
  • Nassar HR, Namour AE, Shafik HE, El Sayed AS, Kamel SM, Moneer MM, Zakhary NI. Prognostic significance of plasma osteopontin level in breast cancer patients. HeSMO. 2015;6 (1):27-32
  • Patouraux S, Bonnafous S, Voican CS, Anty R, Saint-Paul MC, Rosenthal-Allieri MA, Ag
Related Products Docs